Monographie - Trastuzumab

Son güncelleme :
28/04/2024

Trastuzumab

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Herceptin	Almanya, Amerika Birleşik Devletleri, Arjantin, Avustralya, Avusturya, Belçika, Birleşik Arap Emirlikleri, Brezilya, Büyük Britanya, Danimarka, Ekvador, Fas, Finlandiya, Fransa, Hollanda, İran, İrlanda, İspanya, İsveç, İsviçre, İtalya, İzlanda, Japonya, Kanada, Kolombiya, Lüksemburg, Macaristan, Malezya, Meksika, Mısır, Norveç, Peru, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Türkiye, Yeni Zelanda, Yunanistan
Herclon	Peru
Hertraz	Şili
Herzuma	Almanya, Amerika Birleşik Devletleri, Belçika, Büyük Britanya, Fransa, İspanya
Kanjinti	Almanya, Belçika, Büyük Britanya, İspanya
Trastuzumab Baxter	Yeni Zelanda
Trazimera	Büyük Britanya

Kaynaklar : Trastuzumab

	Tip	Yayın
2296	Laboratuar	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2975	Afiş	Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschopf U, Mahler H.C. In-Use stability of herceptin for subcutaneous injection with different administration materials. ESCP 2014 2014
3077	Laboratuar	Trastuzumab (Herceptin®) – Summary of Product Characteristics Roche 2019
3113	Kitap	Herceptin Compendium Suisse des m?dicaments 2010
3258	Dergi	Kaiser J, Krämer I. Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. Int J Pharm Compound 2011 ; 15, 6 : 515-520.
3343	Afiş	Vieillard V, da Silva R, Astier A, Paul M. Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C. ECOP Congress, Budapest, Hungary 2012
3366	Dergi	Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2012 ; DOI 10.1002 / jps.23403
3386	Dergi	Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm 2013 ; 448: 101-104.
3647	Laboratuar	Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics Roche 2019
3849	Dergi	Pabari R.M, Ryan B, Ahmad W, Ramtoola Z. Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. Curr Pharm Biotech 2013 ; 14, 2: 220-225.
4163	Dergi	Nalenz H, K?pf E, Dietel E. Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. Int J Pharm Compound 2018 22;5:417-423
4191	Dergi	Vieillard V, Astier A, Paul M. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at varioustemperatures. GaBI Journal 2018
4194	Dergi	Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y. In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. Bio Drugs 2018 32;619-625
4271	Dergi	Yun J, Kim J, Chung J, Hwang S-J, Park S-J. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties Adv Ther 2019
4396	Dergi	Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions. GaBI Journal 2020 ; 9, 1:
4477	Dergi	Crampton S, Polozoxa A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J,,Goss M. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. GaBI Journal 2020 ; 9, 1: 5-13.
4493	Dergi	Le Guyader G, Vieillard V, Paul M. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. J Oncol Pharm Practice 2020
4649	Dergi	Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddini J, Hippenmeyer J. Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices. GaBI Journal 2021 ; 10, 4
4754	Dergi	Weiser S, Burns C, Zartler E Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions. J Oncol Pharm Practice 2023 ;29,3:

Mentions Légales